| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
Galocitabine manufacturers
- Galocitabine
-
- $83.00
-
2026-05-18
- CAS:124012-42-6
- Purity: 99.89%
- Supply Ability: 10g
|
| | Galocitabine Basic information |
| Product Name: | Galocitabine | | Synonyms: | Galocitabine;Ro 09-1390;Galocytabine;N-(3,4,5-Trimethoxybenzoyl)-5'-deoxy-5-fluorocytidine;5'-Deoxy-5-fluoro-N4-(3,4,5-trimethoxybenzoyl)cytidine;N-[1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydro-4-pyrimidinyl]-3,4,5-trimethoxybenzamide;Cytidine, 5'-deoxy-5-fluoro-N-(3,4,5-trimethoxybenzoyl)-;Neofrutulon | | CAS: | 124012-42-6 | | MF: | C19H22FN3O8 | | MW: | 439.394 | | EINECS: | | | Product Categories: | | | Mol File: | 124012-42-6.mol |  |
| | Galocitabine Chemical Properties |
| density | 1.52±0.1 g/cm3(Predicted) | | pka | 6.80±0.40(Predicted) |
| | Galocitabine Usage And Synthesis |
| Uses | Galocitabine (Ro 09-1390) is a nucleoside analog with anticancer and antiviral activity[1]. | | References | [1] T Funaki, et al. Simultaneous determination of a new anticancer drug galocitabine and its metabolites in blood by high-performance liquid chromatography. J Pharm Biomed Anal. 1993, 11, 4, 5. DOI:10.1016/0731-7085(93)80032-v
[2] Rongkun Liu, et al. Synthesis of Nucleosides and Deoxynucleosides via Gold(I)-Catalyzed N-Glycosylation of Glycosyl (Z)-Ynenoates. Org Lett. 2022, 24, 51. DOI:10.1021/acs.orglett.2c03964 |
| | Galocitabine Preparation Products And Raw materials |
|